Physician profile
Christopher Michael Porter
NPI 1598831760
$8,383.62
in general payments reported to CMS, 2019-2025
57 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $766 · 2021: $1,453 · 2022: $1,137 · 2023: $1,071 · 2024: $1,514 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,123 · Education: $91.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,122.72 |
| Education | $91.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,065.77 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,000.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $849.60 | 2021-2025 | |
| Lilly USA, LLC | $766.19 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $402.95 | 2019-2023 | |
| Pfizer INC. | $344.91 | 2019-2025 | |
| Sk Life Science, INC. | $336.26 | 2022-2025 | |
| Astellas Pharma US INC | $275.80 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $255.76 | 2022-2025 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $255.46 | 2019-2022 | |
| Mylan Specialty L.P. | $251.80 | 2021-2022 | |
| Glaxosmithkline, LLC. | $233.19 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lundbeck LLC | $206.16 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $176.05 | 2022-2025 | Austedo Xr, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $151.31 | 2023-2025 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.